Orexigen pockets $100M in milestone cash for Contrave

It took a while, but San Diego-based Orexigen ($OREX) has just earned a $70 million milestone from its deal with Takeda on the obesity drug Contrave. The milestone was triggered by the shipment of the drug to wholesalers as the partners prep an ambitious market launch. Just weeks ago Orexigen also won a $30 million milestone for the newly approved therapy--naltrexone HCI and bupropion HCI extended release--which hopes to succeed where its rivals have failed badly. Takeda believes its deployment of 900 sales reps will be key to their success. Report

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.